Medifocus Inc (MDFZF) 0.0326 $MDFZF
Medifocus, Inc. Signs Research & Development and Manufacturing Agreement for Its Patented Technology of Heat-Activated and Tumor Targeted Immunotherapy and Gene Therapy
Marketwire Canada - Wed Jan 13, 7:00AM CST
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) ("Medifocus" or the "Company"
, a biotechnology company with a portfolio of medical products encompassing thermotherapy systems for the treatment of Benign Prostatic Hyperplasia (BPH) and Breast Cancer, and heat activated molecular therapeutics today announced that the Company has entered into an agreement (the "Agreement" for the commercial development, and manufacturing of Medifocus' patented heat-activated and tumor targeted immuno-therapeutics with the Yuanxing Bio-Pharm Science & Technology Co. Ltd. (Yuanxing) in Shenzhen, China.
MFS.VN: 0.035 (unch)
Medifocus, Inc. Announces the Engagement of Tanaka Kapec Design Group, Inc. as Lead Designer of Next Generation of Prolieve(R) Thermodilatation System
Marketwire Canada - Mon Jan 11, 7:00AM CST
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) (Medifocus or the Company) a biotechnology company with a portfolio of medical products encompassing thermotherapy systems for the treatment of Benign Prostatic Hyperplasia (BPH) and Breast Cancer, and Heat Activated Tumor Targeted Immunotherapy and Gene Therapy, today announced that the Company has engaged Tanaka Kapec Design Group, Inc. (TKDG) as lead designer for the Company's next generation Prolieve(R) Thermodilatation System for treatment of BPH.
MFS.VN: 0.035 (unch)
Medifocus Inc. Announces Grant of Incentive Options and Completion of Shares for Debt Transaction
CNW Group - Thu Dec 31, 10:30AM CST
Medifocus Inc. ("Medifocus" or the "Company" (TSXV: MFS) and (OTCQX: MDFZF) announced today that, subject to regulatory approval, it has granted incentive stock options to the directors and officers of the Company to purchase an aggregate of 10,100,000 common shares under the Company's Stock Option Plan. Each Option is exercisable at a price of $0.08 per common share, expire five years from their date of grant and vests on the date of grant.
MFS.VN: 0.035 (unch)
Medifocus, Inc. Announces Closing of First Tranche of Units Offering
Marketwire Canada - Mon Dec 14, 9:59AM CST
Medifocus Inc. (TSX VENTURE: MFS) (OTCQX: MDFZF) ("Medifocus" or the "Company" announces that it has completed the first tranche of its previously announced private placement. The Company issued 78.5 Units at a price of U.S. $10,000 per Unit for gross proceeds of U.S. $785,000. Each Unit is comprised of 200,000 common shares of the Company, and 100,000 Series F Common Share purchase warrants. Each Series F Common Share purchase warrant entitles the holder to purchase one additional Common Share at a price of U.S. $0.10 for a period of 24 months following the completion of the Offering. If, at any time prior to the warrants' expiration date, the daily volume weighted average trading price of the Common Shares exceeds U.S. $0.20 on the OTCQX in the United States, or its equivalent in Canadian dollars on the TSX Venture Exchange in Canada for at least 10 consecutive trading days, Medifocus may, within 30 days of such occurrence, give an expiry acceleration notice to the holders of warrants and, if it does so, the warrants will, unless exercised, expire on the 30th day after the expiry acceleration notice is given. Medifocus paid finder's fees of US $48,000.
MFS.VN: 0.035 (unch)
Medifocus, Inc. Announces Financial Results for the Six Months Ending September 30, 2015
Marketwire Canada - Mon Dec 07, 8:53AM CST
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) (Medifocus or the Company) reported its financial results for the second fiscal quarter ending September 30, 2015.
MFS.VN: 0.035 (unch)
Medifocus Inc. Presenting Papers at Biotechnology and Information Technology's 5th Annual Symposium in Beijing, October 20-22, 2015
Marketwire Canada - Mon Oct 19, 7:30AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS.V), a medical systems and devices company that develops and commercializes focused heat thermotherapy systems for the treatment of Benign Prostatic Hyperplasia (BPH) and Breast Cancer, today announced that two of the Company's senior executives are attending and presenting scientific papers during the Biotechnology & Information Technology (BIT)'s 5th Annual Symposium on Drug Delivery Systems to be held October 20-22 in Beijing, China.
Medifocus Inc. Announces Exclusive Agreement With Major Academic Medical Center to License Technology to Develop Heat-Activated and Tumor-Targeted Immunotherapy and Gene Therapy
Marketwired - Thu Oct 15, 3:34PM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS), a medical systems and devices company that develops and commercializes focused heat thermotherapy systems for the treatment of Benign Prostatic Hyperplasia (BPH) and breast cancer, today announced that the Company has formally entered into an exclusive license agreement with Duke University regarding Heat-Activated and Tumor-Targeted Immunotherapy and Gene Therapy. The exclusive license agreement pertains to the Patent Rights of a Duke invention for the development of heat-activated and tumor-targeted immunotherapy and gene therapy for the treatment of cancers and other diseases.
MFS.VN: 0.035 (unch)
GroGenesis Announces New Chairman of the Board of Directors
Marketwired - Thu Oct 08, 12:42PM CDT
GroGenesis, Inc., (OTCQB: GROG), the rights holder, developer and manufacturer of innovative agricultural enhancement products marketed under the trade names "AgraBurst" and "AgraBlast," announced today the appointment of Grant B. Walsh as a Director and Chairman of the Board of Directors of GroGenesis, effective immediately.
Medifocus, Inc. Presentation Now Available for On-Demand Viewing
CNW Group - Tue Oct 06, 7:00AM CDT
Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation
MFS.VN: 0.035 (unch)
Medifocus, Inc. Announces Approach of Major Milestone of 100,000 Prolieve(R) Treatments
Marketwire Canada - Wed Sep 30, 10:04AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS), a biotechnology company with a portfolio of medical technologies that utilizes heat-activation to treat conditions ranging from urological problems to breast cancer treatment and extends to gene therapy, announced today that, based on the total number of single use Prolieve(R) Kits sold to date, a milestone of 100,000 men with Benign Prostatic Hyperplasia (BPH) treated with the Prolieve(R) system, is rapidly approaching. Prolieve(R) offers a unique "Thermodilatation" treatment for BPH. Thermodilatation is a combinational therapy using Transurethral Microwave Therapy (TUMT) together with cooled and pressurized balloon dilatation therapy simultaneously.
MFS.VN: 0.035 (unch)
Medifocus, Inc. to Present Live via Webcast at VirtualInvestorConferences.com on October 1, 2015 at 10:45am ET
PR Newswire - Tue Sep 29, 7:55AM CDT
Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com
MFS.VN: 0.035 (unch)
Medifocus Inc. Announces Units Offering
CNW Group - Mon Sep 28, 4:07PM CDT
Medifocus Inc. (TSX VENTURE:MFS) (OTCQX:MDFZF) ("Medifocus" or the "Company" announces, subject to regulatory approval, a non-brokered private placement of up to 500 units (the "Units" at a price of U.S. $10,000 per Unit for anticipated gross proceeds of up to U.S. $5,000,000 (the Offering). Each Unit is comprised of 200,000 common shares of the Company, and 100,000 Series F Common Share purchase warrants. Each Series F Common Share purchase warrant entitles the holder to purchase one additional Common Share at a price of U.S. $0.10 for a period of 24 months following the completion of the Offering. If, at any time prior to the warrants' expiration date, the daily volume weighted average trading price of the Common Shares exceeds U.S. $0.20 on the OTCQX in the United States, or its equivalent in Canadian dollars on the TSX Venture Exchange in Canada for at least 10 consecutive trading days, Medifocus may, within 30 days of such occurrence, give an expiry acceleration notice to the holders of warrants and, if it does so, the warrants will, unless exercised, expire on the 30th day after the expiry acceleration notice is given. Medifocus may pay finder's fees equal to 7% of the gross proceeds.
MFS.VN: 0.035 (unch)
OTC Markets Group to Host Virtual Investor Conference for OTCQX Life Science Companies - October 1
PR Newswire - Mon Sep 28, 8:00AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial markets for 10,000 U.S. and global securities, today announced its second in a series of online investor conferences for companies traded on the OTCQX® Best Market through its partnership with VirtualInvestorConferences.com, a cooperative venture of PR Newswire and Better Investing(TM).
CDXC: 5.50 (-0.26)
Medifocus, Inc. Signs Research & Development and Manufacturing Agreement for Its Patented Technology of Heat-Activated and Tumor Targeted Immunotherapy and Gene Therapy
Marketwire Canada - Wed Jan 13, 7:00AM CST
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) ("Medifocus" or the "Company"
, a biotechnology company with a portfolio of medical products encompassing thermotherapy systems for the treatment of Benign Prostatic Hyperplasia (BPH) and Breast Cancer, and heat activated molecular therapeutics today announced that the Company has entered into an agreement (the "Agreement" for the commercial development, and manufacturing of Medifocus' patented heat-activated and tumor targeted immuno-therapeutics with the Yuanxing Bio-Pharm Science & Technology Co. Ltd. (Yuanxing) in Shenzhen, China. MFS.VN: 0.035 (unch)
Medifocus, Inc. Announces the Engagement of Tanaka Kapec Design Group, Inc. as Lead Designer of Next Generation of Prolieve(R) Thermodilatation System
Marketwire Canada - Mon Jan 11, 7:00AM CST
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) (Medifocus or the Company) a biotechnology company with a portfolio of medical products encompassing thermotherapy systems for the treatment of Benign Prostatic Hyperplasia (BPH) and Breast Cancer, and Heat Activated Tumor Targeted Immunotherapy and Gene Therapy, today announced that the Company has engaged Tanaka Kapec Design Group, Inc. (TKDG) as lead designer for the Company's next generation Prolieve(R) Thermodilatation System for treatment of BPH.
MFS.VN: 0.035 (unch)
Medifocus Inc. Announces Grant of Incentive Options and Completion of Shares for Debt Transaction
CNW Group - Thu Dec 31, 10:30AM CST
Medifocus Inc. ("Medifocus" or the "Company"
(TSXV: MFS) and (OTCQX: MDFZF) announced today that, subject to regulatory approval, it has granted incentive stock options to the directors and officers of the Company to purchase an aggregate of 10,100,000 common shares under the Company's Stock Option Plan. Each Option is exercisable at a price of $0.08 per common share, expire five years from their date of grant and vests on the date of grant. MFS.VN: 0.035 (unch)
Medifocus, Inc. Announces Closing of First Tranche of Units Offering
Marketwire Canada - Mon Dec 14, 9:59AM CST
Medifocus Inc. (TSX VENTURE: MFS) (OTCQX: MDFZF) ("Medifocus" or the "Company"
announces that it has completed the first tranche of its previously announced private placement. The Company issued 78.5 Units at a price of U.S. $10,000 per Unit for gross proceeds of U.S. $785,000. Each Unit is comprised of 200,000 common shares of the Company, and 100,000 Series F Common Share purchase warrants. Each Series F Common Share purchase warrant entitles the holder to purchase one additional Common Share at a price of U.S. $0.10 for a period of 24 months following the completion of the Offering. If, at any time prior to the warrants' expiration date, the daily volume weighted average trading price of the Common Shares exceeds U.S. $0.20 on the OTCQX in the United States, or its equivalent in Canadian dollars on the TSX Venture Exchange in Canada for at least 10 consecutive trading days, Medifocus may, within 30 days of such occurrence, give an expiry acceleration notice to the holders of warrants and, if it does so, the warrants will, unless exercised, expire on the 30th day after the expiry acceleration notice is given. Medifocus paid finder's fees of US $48,000. MFS.VN: 0.035 (unch)
Medifocus, Inc. Announces Financial Results for the Six Months Ending September 30, 2015
Marketwire Canada - Mon Dec 07, 8:53AM CST
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) (Medifocus or the Company) reported its financial results for the second fiscal quarter ending September 30, 2015.
MFS.VN: 0.035 (unch)
Medifocus Inc. Presenting Papers at Biotechnology and Information Technology's 5th Annual Symposium in Beijing, October 20-22, 2015
Marketwire Canada - Mon Oct 19, 7:30AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS.V), a medical systems and devices company that develops and commercializes focused heat thermotherapy systems for the treatment of Benign Prostatic Hyperplasia (BPH) and Breast Cancer, today announced that two of the Company's senior executives are attending and presenting scientific papers during the Biotechnology & Information Technology (BIT)'s 5th Annual Symposium on Drug Delivery Systems to be held October 20-22 in Beijing, China.
Medifocus Inc. Announces Exclusive Agreement With Major Academic Medical Center to License Technology to Develop Heat-Activated and Tumor-Targeted Immunotherapy and Gene Therapy
Marketwired - Thu Oct 15, 3:34PM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS), a medical systems and devices company that develops and commercializes focused heat thermotherapy systems for the treatment of Benign Prostatic Hyperplasia (BPH) and breast cancer, today announced that the Company has formally entered into an exclusive license agreement with Duke University regarding Heat-Activated and Tumor-Targeted Immunotherapy and Gene Therapy. The exclusive license agreement pertains to the Patent Rights of a Duke invention for the development of heat-activated and tumor-targeted immunotherapy and gene therapy for the treatment of cancers and other diseases.
MFS.VN: 0.035 (unch)
GroGenesis Announces New Chairman of the Board of Directors
Marketwired - Thu Oct 08, 12:42PM CDT
GroGenesis, Inc., (OTCQB: GROG), the rights holder, developer and manufacturer of innovative agricultural enhancement products marketed under the trade names "AgraBurst" and "AgraBlast," announced today the appointment of Grant B. Walsh as a Director and Chairman of the Board of Directors of GroGenesis, effective immediately.
Medifocus, Inc. Presentation Now Available for On-Demand Viewing
CNW Group - Tue Oct 06, 7:00AM CDT
Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation
MFS.VN: 0.035 (unch)
Medifocus, Inc. Announces Approach of Major Milestone of 100,000 Prolieve(R) Treatments
Marketwire Canada - Wed Sep 30, 10:04AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS), a biotechnology company with a portfolio of medical technologies that utilizes heat-activation to treat conditions ranging from urological problems to breast cancer treatment and extends to gene therapy, announced today that, based on the total number of single use Prolieve(R) Kits sold to date, a milestone of 100,000 men with Benign Prostatic Hyperplasia (BPH) treated with the Prolieve(R) system, is rapidly approaching. Prolieve(R) offers a unique "Thermodilatation" treatment for BPH. Thermodilatation is a combinational therapy using Transurethral Microwave Therapy (TUMT) together with cooled and pressurized balloon dilatation therapy simultaneously.
MFS.VN: 0.035 (unch)
Medifocus, Inc. to Present Live via Webcast at VirtualInvestorConferences.com on October 1, 2015 at 10:45am ET
PR Newswire - Tue Sep 29, 7:55AM CDT
Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com
MFS.VN: 0.035 (unch)
Medifocus Inc. Announces Units Offering
CNW Group - Mon Sep 28, 4:07PM CDT
Medifocus Inc. (TSX VENTURE:MFS) (OTCQX:MDFZF) ("Medifocus" or the "Company"
announces, subject to regulatory approval, a non-brokered private placement of up to 500 units (the "Units" at a price of U.S. $10,000 per Unit for anticipated gross proceeds of up to U.S. $5,000,000 (the Offering). Each Unit is comprised of 200,000 common shares of the Company, and 100,000 Series F Common Share purchase warrants. Each Series F Common Share purchase warrant entitles the holder to purchase one additional Common Share at a price of U.S. $0.10 for a period of 24 months following the completion of the Offering. If, at any time prior to the warrants' expiration date, the daily volume weighted average trading price of the Common Shares exceeds U.S. $0.20 on the OTCQX in the United States, or its equivalent in Canadian dollars on the TSX Venture Exchange in Canada for at least 10 consecutive trading days, Medifocus may, within 30 days of such occurrence, give an expiry acceleration notice to the holders of warrants and, if it does so, the warrants will, unless exercised, expire on the 30th day after the expiry acceleration notice is given. Medifocus may pay finder's fees equal to 7% of the gross proceeds. MFS.VN: 0.035 (unch)
OTC Markets Group to Host Virtual Investor Conference for OTCQX Life Science Companies - October 1
PR Newswire - Mon Sep 28, 8:00AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial markets for 10,000 U.S. and global securities, today announced its second in a series of online investor conferences for companies traded on the OTCQX® Best Market through its partnership with VirtualInvestorConferences.com, a cooperative venture of PR Newswire and Better Investing(TM).
CDXC: 5.50 (-0.26)
